FLT3 p.Asp835His
c.2503G>C · rs121913488 · VCV16273
Computational evidence
| Protein change | ||
| AlphaMissense | 0.9725 | likely pathogenic ✓ concordant with ClinVar · top 8% in FLT3 |
|---|---|---|
| REVEL | 0.878 | moderately pathogenic-leaning |
| SaProt | LLR -7.11 | tolerated |
| ⇒ AlphaMissense and REVEL call this damaging; SaProt does not. | ||
| Splicing | ||
| SpliceAI | — | not assessed · no allele here is in the release |
| Constraint at this position | ||
| Conservation | phyloP 7.6 | GERP 2.3, phastCons 1 |
| Regional constraint | o/e 0.90 | unconstrained · MANE · 96 kb · p 0.00044 · regional, not allelic |
| Overall | ||
| CADD | 29.4 | PHRED · no single calibrated threshold — expert panels disagree |
AlphaMissense carries the ACMG weight for missense; REVEL and SaProt are independent agreement signals.
Population frequency
Absent from gnomAD v4.1. Not observed in any sequenced alleles — a rarity signal (ACMG PM2-supporting), not evidence of pathogenicity on its own.
Cancer therapy — CIViC
| Disease | Therapies | Level | Significance |
|---|---|---|---|
| Acute Myeloid Leukemia | Ponatinib,Quizartinib | D | Resistance |
| Acute Myeloid Leukemia | SU5614 | D | Resistance |
| Acute Myeloid Leukemia | Quizartinib,Sorafenib | B | Resistance |
| Acute Myeloid Leukemia | Sorafenib | B | Resistance |
| Acute Myeloid Leukemia | Midostaurin,Chemotherapy | A | Sensitivity/Response |
| Acute Myeloid Leukemia | Sunitinib | C | Sensitivity/Response |
| Acute Myeloid Leukemia | Sunitinib | C | Sensitivity/Response |
| Acute Myeloid Leukemia | Sunitinib | D | Sensitivity/Response |
Variant & gene context
- Gene
- FLT3
- Protein
- p.Asp835His
- Coding
- c.2503G>C
- MANE Select
- NM_004119
- dbSNP
- rs121913488
- Type
- single nucleotide variant
- Location
- chr13:28018505 (GRCh38)
- Gene constraint
- LOEUF 0.468 · pLI 1.00 (gnomAD)
- Structure
- AlphaFold pLDDT 76.19 · 11 PDB
- Residue 835
- a UniProt-annotated variant site (in acute lymphoblastic leukemia patients and acute myelogenous leukemia patients; somatic mutation; constitutively activated); a UniProt-annotated variant site (in acute lymphoblastic leukemia patients and in acute myelogenous leukemia patients; somatic mutation; constitutively activated); the protein kinase domain
Similar variants
- FLT3 p.Asp835Asn Pathogenic ⚠ same residue
- FLT3 p.Asp835Glu Pathogenic ⚠ same residue
- FLT3 p.Asp835Tyr Pathogenic same residue
- FLT3 p.Asp835Val Pathogenic same residue
- FLT3 p.Asp835del Pathogenic same residue
- FLT3 p.Arg845Gly Likely pathogenic ★ same condition
- FLT3 p.Tyr572Cys Likely pathogenic ★ ⚠ same condition
- FLT3 p.Ser840_Asn841insGlySer Pathogenic same condition
Built on 18 open, versioned datasets — ClinVar, gnomAD, AlphaMissense, REVEL, ClinGen & more — plus Sugi Variant's own cross-source analysis. Source data 2026-01–2026-10, ClinVar 2026-10. Full sources & versions →
Cite Sugi Variant
Gür T. Sugi Variant: A Deterministic Per-Variant Germline Reference from a Knowledge Graph for Humans and AI Agents. 2026. doi:10.5281/zenodo.21509445. This variant: https://sugi.bio/variant/flt3-p-asp835his (accessed [today's date]).
Preprint & method: sugi.bio/variant/method Machine-readable: this page as Markdown